Prophylactic treatment with VT-1161 protects immunosuppressed mice from rhizopus arrhizus var. Arrhizus infection

Teclegiorgis Gebremariam; Sondus Alkhazraji; Lin Lin; Nathan P. Wiederhold; Edward P. Garvey; William J. Hoekstra; Robert J. Schotzinger; Thomas F. Patterson; Scott G. Filler; Ashraf S. Ibrahim

doi:10.1128/AAC.00390-17

Prophylactic treatment with VT-1161 protects immunosuppressed mice from rhizopus arrhizus var. Arrhizus infection

Teclegiorgis Gebremariam
, Sondus Alkhazraji
, Lin Lin
, Nathan P. Wiederhold
, Edward P. Garvey
, William J. Hoekstra
, Robert J. Schotzinger
, Thomas F. Patterson
, Scott G. Filler
, Ashraf S. Ibrahim

Research output: Contribution to journal › Article › peer-review

35 Scopus citations

Abstract

We compared prophylactic or continuous therapy with the investiga-tional drug VT-1161 to that with posaconazole in treating murine mucormycosis due to Rhizopus arrhizus var. arrhizus. In the prophylaxis studies, only VT-1161 resulted in improved survival and lowered tissue fungal burden of immunosuppressed infected mice. In the continuous therapy, VT-1161 outperformed posaconazole in prolonging mouse survival time despite its comparable effect in lowering tissue fungal burden. These results support the further development of VT-1161 against mucormycosis.

Original language	English (US)
Article number	e00390-17
Journal	Antimicrobial agents and chemotherapy
Volume	61
Issue number	9
DOIs	https://doi.org/10.1128/AAC.00390-17
State	Published - Sep 2017

Keywords

Mucormycosis
Murine
Prophylaxis
Rhizopus arrhizus
VT-1161

ASJC Scopus subject areas

Pharmacology (medical)
Infectious Diseases
Pharmacology

Access to Document

10.1128/AAC.00390-17

Cite this

Gebremariam, T., Alkhazraji, S., Lin, L., Wiederhold, N. P., Garvey, E. P., Hoekstra, W. J., Schotzinger, R. J., Patterson, T. F., Filler, S. G., & Ibrahim, A. S. (2017). Prophylactic treatment with VT-1161 protects immunosuppressed mice from rhizopus arrhizus var. Arrhizus infection. Antimicrobial agents and chemotherapy, 61(9), Article e00390-17. https://doi.org/10.1128/AAC.00390-17

@article{4ed17ce7f63f46108abba6b76c35ca8c,

title = "Prophylactic treatment with VT-1161 protects immunosuppressed mice from rhizopus arrhizus var. Arrhizus infection",

abstract = "We compared prophylactic or continuous therapy with the investiga-tional drug VT-1161 to that with posaconazole in treating murine mucormycosis due to Rhizopus arrhizus var. arrhizus. In the prophylaxis studies, only VT-1161 resulted in improved survival and lowered tissue fungal burden of immunosuppressed infected mice. In the continuous therapy, VT-1161 outperformed posaconazole in prolonging mouse survival time despite its comparable effect in lowering tissue fungal burden. These results support the further development of VT-1161 against mucormycosis.",

keywords = "Mucormycosis, Murine, Prophylaxis, Rhizopus arrhizus, VT-1161",

author = "Teclegiorgis Gebremariam and Sondus Alkhazraji and Lin Lin and Wiederhold, \{Nathan P.\} and Garvey, \{Edward P.\} and Hoekstra, \{William J.\} and Schotzinger, \{Robert J.\} and Patterson, \{Thomas F.\} and Filler, \{Scott G.\} and Ibrahim, \{Ashraf S.\}",

year = "2017",

month = sep,

doi = "10.1128/AAC.00390-17",

language = "English (US)",

volume = "61",

journal = "Antimicrobial agents and chemotherapy",

issn = "0066-4804",

publisher = "American Society for Microbiology",

number = "9",

}

TY - JOUR

T1 - Prophylactic treatment with VT-1161 protects immunosuppressed mice from rhizopus arrhizus var. Arrhizus infection

AU - Gebremariam, Teclegiorgis

AU - Alkhazraji, Sondus

AU - Lin, Lin

AU - Wiederhold, Nathan P.

AU - Garvey, Edward P.

AU - Hoekstra, William J.

AU - Schotzinger, Robert J.

AU - Patterson, Thomas F.

AU - Filler, Scott G.

AU - Ibrahim, Ashraf S.

PY - 2017/9

Y1 - 2017/9

N2 - We compared prophylactic or continuous therapy with the investiga-tional drug VT-1161 to that with posaconazole in treating murine mucormycosis due to Rhizopus arrhizus var. arrhizus. In the prophylaxis studies, only VT-1161 resulted in improved survival and lowered tissue fungal burden of immunosuppressed infected mice. In the continuous therapy, VT-1161 outperformed posaconazole in prolonging mouse survival time despite its comparable effect in lowering tissue fungal burden. These results support the further development of VT-1161 against mucormycosis.

AB - We compared prophylactic or continuous therapy with the investiga-tional drug VT-1161 to that with posaconazole in treating murine mucormycosis due to Rhizopus arrhizus var. arrhizus. In the prophylaxis studies, only VT-1161 resulted in improved survival and lowered tissue fungal burden of immunosuppressed infected mice. In the continuous therapy, VT-1161 outperformed posaconazole in prolonging mouse survival time despite its comparable effect in lowering tissue fungal burden. These results support the further development of VT-1161 against mucormycosis.

KW - Mucormycosis

KW - Murine

KW - Prophylaxis

KW - Rhizopus arrhizus

KW - VT-1161

UR - https://www.scopus.com/pages/publications/85028326528

UR - https://www.scopus.com/pages/publications/85028326528#tab=citedBy

U2 - 10.1128/AAC.00390-17

DO - 10.1128/AAC.00390-17

M3 - Article

C2 - 28652241

AN - SCOPUS:85028326528

SN - 0066-4804

VL - 61

JO - Antimicrobial agents and chemotherapy

JF - Antimicrobial agents and chemotherapy

IS - 9

M1 - e00390-17

ER -

Prophylactic treatment with VT-1161 protects immunosuppressed mice from rhizopus arrhizus var. Arrhizus infection

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this